162 related articles for article (PubMed ID: 17539749)
1. Transdermal oxybutynin: a review.
Shaw GL; Patel HR
Expert Opin Drug Metab Toxicol; 2007 Jun; 3(3):435-9. PubMed ID: 17539749
[TBL] [Abstract][Full Text] [Related]
2. Transdermal drug delivery treatment for overactive bladder.
Dmochowski RR; Starkman JS; Davila GW
Int Braz J Urol; 2006; 32(5):513-20. PubMed ID: 17081319
[TBL] [Abstract][Full Text] [Related]
3. Transdermal oxybutynin: a new treatment for overactive bladder.
Davila GW
Expert Opin Pharmacother; 2003 Dec; 4(12):2315-24. PubMed ID: 14640930
[TBL] [Abstract][Full Text] [Related]
4. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
Goldenberg MM
Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730
[TBL] [Abstract][Full Text] [Related]
5. Transdermal oxybutynin for overactive bladder.
Davila GW; Starkman JS; Dmochowski RR
Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
[TBL] [Abstract][Full Text] [Related]
6. Oxybutynin gel for the treatment of overactive bladder.
Gomelsky A; Dmochowski RR
Expert Opin Pharmacother; 2012 Jun; 13(9):1337-43. PubMed ID: 22607010
[TBL] [Abstract][Full Text] [Related]
7. Transdermal oxybutynin in the treatment of overactive bladder.
Davila GW
Clin Interv Aging; 2006; 1(2):99-105. PubMed ID: 18044106
[TBL] [Abstract][Full Text] [Related]
8. Oxybutynin topical and transdermal formulations: an update.
Staskin DR; Salvatore S
Drugs Today (Barc); 2010 Jun; 46(6):417-25. PubMed ID: 20571610
[TBL] [Abstract][Full Text] [Related]
9. Transdermal oxybutynin.
Baldwin CM; Keating GM
Drugs; 2009; 69(3):327-37. PubMed ID: 19275276
[TBL] [Abstract][Full Text] [Related]
10. The evolution of transdermal therapy for overactive bladder.
Sand PK
Curr Urol Rep; 2009 Sep; 10(5):338-41. PubMed ID: 19709479
[TBL] [Abstract][Full Text] [Related]
11. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.
Staskin DR; Robinson D
Expert Opin Pharmacother; 2009 Dec; 10(18):3103-11. PubMed ID: 19954278
[TBL] [Abstract][Full Text] [Related]
12. Evolution of transdermal oxybutynin in the treatment of overactive bladder.
Sahai A; Mallina R; Dowson C; Larner T; Khan MS
Int J Clin Pract; 2008 Jan; 62(1):167-70. PubMed ID: 18173821
[TBL] [Abstract][Full Text] [Related]
13. Transdermal oxybutynin: for overactive bladder.
Bang LM; Easthope SE; Perry CM
Drugs Aging; 2003; 20(11):857-64. PubMed ID: 12964892
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference.
Dmochowski RR; Newman DK; Sand PK; Rudy DC; Caramelli KE; Thomas H; Hoel G
Clin Drug Investig; 2011; 31(8):559-571. PubMed ID: 21721591
[TBL] [Abstract][Full Text] [Related]
15. [Maintenance of the efficacy of the oxybutynin patch for the treatment of overactive bladder syndrome despite the change in the area of application: study of four cases.].
Merino Salas S
Arch Esp Urol; 2018 Jun; 71(5):502-505. PubMed ID: 29889041
[TBL] [Abstract][Full Text] [Related]
16. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability.
Yarker YE; Goa KL; Fitton A
Drugs Aging; 1995 Mar; 6(3):243-62. PubMed ID: 7620236
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers.
Zobrist RH; Schmid B; Feick A; Quan D; Sanders SW
Pharm Res; 2001 Jul; 18(7):1029-34. PubMed ID: 11496941
[TBL] [Abstract][Full Text] [Related]
18. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.
Schaefer W
Int J Urol; 2007 Jul; 14(7):670; author reply 670-1. PubMed ID: 17645621
[No Abstract] [Full Text] [Related]
20. Treatments for overactive bladder: focus on pharmacotherapy.
Geoffrion R;
J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
